Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

NEXT STORY
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies
PREV STORY
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global research antibody market to expand with a CAGR of 6.2% through 2027

author_avatar
NASDAQ Market News

TESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

author_avatar
NASDAQ Market News

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

author_avatar
NASDAQ Market News